These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37809105)

  • 1. Cardiovascular impairment in Shiga-toxin-2-induced experimental hemolytic-uremic syndrome: a pilot study.
    Neu C; Wissuwa B; Thiemermann C; Coldewey SM
    Front Immunol; 2023; 14():1252818. PubMed ID: 37809105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS).
    Khalid M; Andreoli S
    Pediatr Nephrol; 2019 Dec; 34(12):2495-2507. PubMed ID: 30382336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Genomics of Shiga Toxin-Producing Escherichia coli Strains Isolated from Pediatric Patients with and without Hemolytic Uremic Syndrome from 2000 to 2016 in Finland.
    Bai X; Ylinen E; Zhang J; Salmenlinna S; Halkilahti J; Saxen H; Narayanan A; Jahnukainen T; Matussek A
    Microbiol Spectr; 2022 Aug; 10(4):e0066022. PubMed ID: 35730965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Shigatoxin 1 protective for the development of Shigatoxin 2-related hemolytic uremic syndrome in children? Data from the ItalKid-HUS Network.
    Ardissino G; Possenti I; Vignati C; Daprai L; Capone V; Brigotti M; Luini MV; Consonni D; Montini G
    Pediatr Nephrol; 2020 Oct; 35(10):1997-2001. PubMed ID: 32734345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury.
    Ozaki M; Kang Y; Tan YS; Pavlov VI; Liu B; Boyle DC; Kushak RI; Skjoedt MO; Grabowski EF; Taira Y; Stahl GL
    Kidney Int; 2016 Oct; 90(4):774-82. PubMed ID: 27378476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).
    Exeni RA; Fernandez-Brando RJ; Santiago AP; Fiorentino GA; Exeni AM; Ramos MV; Palermo MS
    Pediatr Nephrol; 2018 Nov; 33(11):2057-2071. PubMed ID: 29372302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental In Vivo Models of Bacterial Shiga Toxin-Associated Hemolytic Uremic Syndrome.
    Jeong YJ; Park SK; Yoon SJ; Park YJ; Lee MS
    J Microbiol Biotechnol; 2018 Sep; 28(9):1413-1425. PubMed ID: 29926707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Shiga toxin production by hemolytic-uremic syndrome-associated and bovine-associated Shiga toxin-producing Escherichia coli isolates.
    Ritchie JM; Wagner PL; Acheson DW; Waldor MK
    Appl Environ Microbiol; 2003 Feb; 69(2):1059-66. PubMed ID: 12571029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide association study of hemolytic uremic syndrome causing Shiga toxin-producing Escherichia coli from Sweden, 1994-2018.
    Matussek A; Mernelius S; Chromek M; Zhang J; Frykman A; Hansson S; Georgieva V; Xiong Y; Bai X
    Eur J Clin Microbiol Infect Dis; 2023 Jun; 42(6):771-779. PubMed ID: 37103716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2.
    Wijnsma KL; Schijvens AM; Rossen JWA; Kooistra-Smid AMDM; Schreuder MF; van de Kar NCAJ
    Pediatr Nephrol; 2017 Jul; 32(7):1263-1268. PubMed ID: 28343354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperhydration to Improve Kidney Outcomes in Children with Shiga Toxin-Producing E. coli Infection: a multinational embedded cluster crossover randomized trial (the HIKO STEC trial).
    Freedman SB; Schnadower D; Estes M; Casper TC; Goldstein SL; Grisaru S; Pavia AT; Wilfond BS; Metheney M; Kimball K; Tarr PI;
    Trials; 2023 May; 24(1):359. PubMed ID: 37245030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bloody Diarrhea and Shiga Toxin-Producing Escherichia coli Hemolytic Uremic Syndrome in Children: Data from the ItalKid-HUS Network.
    Ardissino G; Vignati C; Masia C; Capone V; Colombo R; Tel F; Daprai L; Testa S; Dodaro A; Paglialonga F; Luini M; Brigotti M; Picicco D; Baldioli C; Pagani F; Ceruti R; Tommasi P; Possenti I; Cresseri D; Consonni D; Montini G; Arghittu M;
    J Pediatr; 2021 Oct; 237():34-40.e1. PubMed ID: 34197890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli infection in Argentina: update of serotypes and genotypes and their relationship with severity of the disease.
    Alconcher LF; Balestracci A; Coccia PA; Suarez ADC; Ramírez FB; Monteverde ML; Perez Y Gutiérrez MG; Carlopio PM; Principi I; Estrella P; Micelli S; Leroy DC; Quijada NE; Seminara C; Giordano MI; Hidalgo Solís SB; Saurit M; Caminitti A; Arias A; Liern M; Rivas M
    Pediatr Nephrol; 2021 Sep; 36(9):2811-2817. PubMed ID: 33604727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Divergent roles of haptoglobin and hemopexin deficiency for disease progression of Shiga-toxin-induced hemolytic-uremic syndrome in mice.
    Pirschel W; Mestekemper AN; Wissuwa B; Krieg N; Kröller S; Daniel C; Gunzer F; Tolosano E; Bauer M; Amann K; Heinemann SH; Coldewey SM
    Kidney Int; 2022 Jun; 101(6):1171-1185. PubMed ID: 35031328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome.
    Orth D; Grif K; Khan AB; Naim A; Dierich MP; Würzner R
    Diagn Microbiol Infect Dis; 2007 Nov; 59(3):235-42. PubMed ID: 17931818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shiga toxin targets the podocyte causing hemolytic uremic syndrome through endothelial complement activation.
    Bowen EE; Hurcombe JA; Barrington F; Keir LS; Farmer LK; Wherlock MD; Ortiz-Sandoval CG; Bruno V; Bohorquez-Hernandez A; Diatlov D; Rostam-Shirazi N; Wells S; Stewart M; Teboul L; Lay AC; Butler MJ; Pope RJP; Larkai EMS; Morgan BP; Moppett J; Satchell SC; Welsh GI; Walker PD; Licht C; Saleem MA; Coward RJM
    Med; 2023 Nov; 4(11):761-777.e8. PubMed ID: 37863058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and characterization of circulating microvesicles containing Shiga toxin type 2 in a rat model of Hemolytic Uremic Syndrome.
    Sacerdoti F; Gomez FD; Jancic C; Lombardo T; Pascuale CA; Moretton MA; Chiappetta DA; Ibarra C; Amaral MM
    Toxicon; 2023 Dec; 236():107349. PubMed ID: 37979924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection.
    Bruyand M; Mariani-Kurkdjian P; Gouali M; de Valk H; King LA; Le Hello S; Bonacorsi S; Loirat C
    Med Mal Infect; 2018 May; 48(3):167-174. PubMed ID: 29054297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Particulate Shiga Toxin 2 in Blood is Associated to the Development of Hemolytic Uremic Syndrome in Children.
    Brigotti M; He X; Carnicelli D; Arfilli V; Porcellini E; Galassi E; Tazzari PL; Ricci F; Patfield SA; Testa S; Paglialonga F; Picicco D; Caprioli A; Scavia G; Morabito S; Ardissino G
    Thromb Haemost; 2020 Jan; 120(1):107-120. PubMed ID: 31858520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the innate repair receptor axis
    Dennhardt S; Pirschel W; Wissuwa B; Imhof D; Daniel C; Kielstein JT; Hennig-Pauka I; Amann K; Gunzer F; Coldewey SM
    Front Immunol; 2022; 13():1010882. PubMed ID: 36211426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.